No Data
No Data
RBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)
Several Factors Lifted Repligen Corporation (RGEN) in Q3
Repligen Launches Novel AVIPure DsRNA Resin in OPUS Pre-packed Columns
RBC Lifts Price Target on Repligen to $207 From $205, Keeps Outperform Rating
Insider Sale: Director at $RGEN (RGEN) Sells 24,246 Shares
Repligen(RGEN.US) Director Sells US$3.39 Million in Common Stock